# Invasive Fungal Disease

**Russell E. Lewis**
Associate Professor of Infectious Diseases
Department of Molecular Medicine
University of Padua

russelledward.lewis@unipd.it
https://github.com/Russlewisbo
Slides and course materials: www.padovaid.com

# Learning Objectives

1. Describe the epidemiology and risk factors for invasive candidiasis, cryptococcosis, aspergillosis, and mucormycosis
2. Identify key clinical presentations and diagnostic approaches for each major invasive fungal infection
3. Select appropriate antifungal therapy based on patient factors, fungal species, and infection site
4. Recognize antifungal drug toxicities and their management
5. Apply evidence-based treatment guidelines to clinical scenarios

# Part 1: Background & Antifungals

# The Hidden Killers




*Sources: GAFFI country burden estimates; Denning, Lancet Infect Dis 2024; Bongomin et al., J Fungi 2017*
*Sub-Saharan Africa bears the greatest burden, driven primarily by HIV-associated cryptococcosis*

# Types of fungal disease



- Allergies
  - e.g., hypersensitivity to mold spores
- Mycotoxicosis
  - Ingestion of fungal toxins in contaminated food or mushrooms

# Mycotoxicosis



Castelfranco Giavera

G | Sabato 4 Novembre 2023
www.gazzettino.it

# Mangia i funghi appena raccolti e sta male: lo salva la figlia

▸L'uomo, di 61 anni, accusa un malore dopo pranzo viene soccorso dalla parente che lancia l'allarme al Suem

**LA DISAVVENTURA** Un uomo raccoglie funghi e poi li mangia ma sono avvelenati. Si sente male ma la figlia chiama il Suem 118 e gli salva la vita. L'appello dei medici: «Fate attenzione»

**CASTELLANA**

Funghi velenosi per pranzo. Salvato dalla figlia. È questa la storia a lieto fine che può raccontare un sessantenne di un comune della Castellana. L'uomo aveva appena raccolto un paniere di funghi e ha pensato bene di cucinarne un po' per servirli a tavola come contorno. Ma si è sentito male praticamente subito dopo averne mangiato. Ha accusato dolori, accompagnati dal vomito. Soprattutto, è stato colto da una pesante sonnolenza e ha detto alla figlia che si buttava a letto a riposare un po'. Lei si è insospettita. Ha prontamente dato l'allarme e ha salvato la vita del papà, portato in ospedale in codice rosso.

**I FATTI**

Ieri mattina l'uomo parte per una battuta alla ricerca di funghi nelle colline attorno a casa. La pioggia di questi giorni e il clima ancora non troppo rigido sono stati due elementi che lo hanno fatto decidere. Fa un discreto bottino e in tarda mattina rientra a casa. È soddisfatto. Pulisce e mette via il prezioso raccolto, decidendo però di preparare qualche fungo per pranzo. Una cottura veloce ed eccoli pronti. Non si accorge che, probabilmente, sono velenosi. Li mangia, soddisfatto. Ma subito dopo si sente male. Lui non collega il fatto che ha mangiato funghi appena raccolti e che si è sentito male. Si dirige verso il letto. Ad insospettirsi, invece, è la figlia che dà l'allarme chiedendo l'aiuto dei sanitari. In casa arriva automedica e ambulanza del Suem 118 di Pedemontana Emergenza Odv.

L'uomo viene trattato subito per la sospetta intossicazione da funghi e si riprende leggermente, riesce a rispondere ai sanitari del Suem e viene, dunque, ricoverato al pronto soccorso dell'ospedale di Castelfranco Veneto dove i medici lo prendono in carico sottoponendolo a valutazioni più approfondite. Non è in pericolo di vita ma deve la sua buona sorte alla figlia che si è insospettita per quello strano malore che aveva colto il genitore subito dopo ave mangiato funghi. Se non fosse intervenuta prontamente l'ambulanza del Suem il destino dell'uomo sarebbe stato segnato.

**GLI OPERATORI SANITARI RIESCONO A STABILIZZARLO E L'UOMO VIENE RICOVERATO IN OSPEDALE**

**INVITO ALLA PRUDENZA**

I medici invitano alla prudenza e, in caso di dubbi, a confrontarsi con l'Ispettorato micologico dell'Usl 2 che assicura, come ogni anno, il controllo sulla commestibilità dei funghi freschi raccolti dai privati. I controlli sono gratuiti e vengono effettuati nei distretti di Treviso (alla Madonnina) a Conegliano (De Gironcoli) e a Montebelluna (in via Alighieri 12).

**Valeria Lipparini**

# Mycoses-Invasive of living tissue by fungus

| Type | Location | Examples |
|---|---|---|
| Superficial | Epidermis, nails | Dermatophytosis |
| Subcutaneous | Dermis, tissue | Sporotrichosis |
| Systemic (primary) | Deep organs | Histoplasmosis |
| Systemic (opportunistic) | Deep organs | Candidiasis, aspergillosis |

# Superfical mycoses



# Subcutaneous mycoses



# Systemic mycoses



# Yeast vs. molds



# Primary (endemic) vs. opportunistic invasive mycoses

**Primary infections**

- Can develop even without underlying immunocompromise; more severe in setting of T-cell mediated immunosuppression (e.g., AIDS)
- "Endemic fungal pathogens"- Histoplasmosis, Blastomycosis, Coccidioidomycosis
  - Molds in the environment- yeast at 37°C
- Endemic areas changing with global warming?

**Opportunistic fungal pathogens**

- Infection in the setting of impaired host immune responses or when inoculated into sterile sites
- Can disseminate to internal organs and the central nervous system
- Associated with high mortality if not diagnosed and treated early

# Most fungi are not adapted to 37°C



*Mutant Cordyceps*

Estimated fungal species: 3-4 million;
Known human pathogenic species: ~150-300 species

# Will this change with global warming: Loss of thermal barrier immunity?

Ophiocordyceps unilaterali: "Zombie-ant fungus"

# WHO fungal priority pathogens list (2022)

**CRITICAL**

- *Cryptococcus neoformans*
- *Candidozyma auris* (*Candida auris*)
- *Aspergillus fumigatus*
- *Candida albicans*

**HIGH**

- *Candida glabrata*
- *Histoplasma* spp.
- Mucorales
- *Fusarium* spp.
- *Candida tropicalis*

**MEDIUM**

- *Scedosporium* spp.
- *Coccidioides* spp.
- *Cryptococcus gattii*
- *Pneumocystis jirovecii*

# Evolution of antifungal therapy




**AmB**

First truly effective antifungal therapy

**Flucytosine**

Combination therapy-yeast infections

**Ketoconazole**

First oral systemic azole

Rev

# Antifungal targets



# Antifungal targets

### Cell Membrane

- **Polyenes**: Bind ergosterol → extract ergosterol →damage cell membrane → cell death
- **Azoles**: Inhibit CYP51 (lanosterol 14-α-demethylase) → depleted ergosterol

### Cell Wall

- **Echinocandins**: Inhibit β-1,3-glucan synthase → cell wall instability

> **Important**
>
> Fungi share eukaryotic machinery with humans - selective toxicity is challenging!

# Antifungal spectrum of activity

| **Agent** | ***Candida*** | ***Aspergillus*** | ***Cryptococcus*** | **Mucorales** |
|---|---|---|---|---|
| Fluconazole | ++ | - | ++ | - |
| Voriconazole | +++ | +++ | + | - |
| Posaconazole | +++ | +++ | + | ++ |
| Isavuconazole | +++ | +++ | + | ++ |
| Echinocandins | +++ | ++ | - | - |
| Amphotericin B | +++ | ++ | +++ | +++ |

# Tissue Distribution Matters!

| Drug | CSF | Eye | Urine | Lung |
|---|---|---|---|---|
| Fluconazole | +++ | +++ | +++ | ++ |
| Voriconazole | ++ | ++ | + | +++ |
| Posaconazole | + | + | - | +++ |
| Echinocandins | - | - | - | + |
| Amphotericin B | +/- | +/- | + | ++ |

> ⚠ **Warning**
>
> **Echinocandins should NOT be used for CNS, ocular, or urinary tract infections!**

Tissue penetration is a major factor in drug selection. The most important clinical limitation is echinocandins: they don't get into CSF, eye, or urine. I've seen patients with candiduria treated with caspofungin - this will fail. Fluconazole remains our best drug for urinary candidiasis. For CNS Aspergillosis, voriconazole is preferred over echinocandins.

# Part 2: Invasive Candidiasis

# A brave surgical resident!

## FUNGÆMIA AND FUNGURIA AFTER ORAL ADMINISTRATION OF CANDIDA ALBICANS

W. KRAUSE
H. MATHEIS K. WULF
FROM THE LANDESKLINIK AND THE STADT-KRANKENHAUS, KASSEL, WEST GERMANY

***Summary*** We have administered approximately $10^{12}$ cells of *Candida albicans* orally to a healthy volunteer. *C. albicans* cells were cultured from blood-samples taken after 3 and 6 hours, and from urine samples taken after $2^3/_4$ and $3^1/_4$ hours, and were found to be identical to the strain administered. There was a transient toxic reaction 2 hours after ingestion, and symptoms of fungæmia were observed up to 9 hours after the start of the test. No lasting damage resulted from the experiment. We conclude that *C. albicans* cells are capable of passing through the intestinal wall, probably by the mechanism of " persorption " and so reach the blood and urine. Since the population of *C. albicans* in the intestine was comparable to that sometimes seen after the use of broad-spectrum antibiotics, it seems likely that antibiotic-induced fungal overpopulation may also result in fungæmia.

(Krause et al.. 1969)

# A brave surgical resident!

*Administration of Candida*

*C. albicans*, strain No. 70310 (Hamburg), was used. A week before, and on the day of the experiment, the strain was investigated for purity by the method of Lodder and Kreger-van Rij (1968) in the mycological laboratory of the Municipal Hospital, Kassel. A total of 80 g. of *C. albicans* was grown in the same laboratory using Sabouraud-dextrose-agar without inhibiting (antibiotic, chemotherapeutic) or growth-stimulating substances (such as vitamins).

As 200 mg. of *C. albicans* was expected to grow on each culture-medium plate, 400 plates were inoculated. The cultures were investigated for bacterial and fungal contamination. From them 80 g. of *Candida* cells (free from culture-medium particles) was taken and a suspension was made in 100 g. of physiological saline solution, producing a liquid-pulpy suspension of 180 g. which contained at least $10^{12}$ *C. albicans* cells. The suspension was prepared half an hour before administration. Shortly before the volunteer swallowed it, the suspension was again sampled for control cultures and slides.

10 minutes after taking the suspension, the volunteer drank 200 ml. of non-carbonated mineral water to wash down the residues and an hour later he drank 400 ml. of physiological saline solution. As the reaction to the massive dose of living pathogenic fungi could not be predicted, all measures for emergency treatment were ready.

After 2 hours the subject felt very ill; at 3, 7, and 9 hours, rectal temperature was 38·7°C; he was shivering and had a severe headache. These signs and symptoms appeared to indicate a toxic reaction and fungæmia. $3^1/_2$

# Resident case cont.

**Results**

The blood-samples taken at 3 and 6 hours each grew 2 *Candida* colonies. 31 colonies grew from the sediment of the urine specimen taken at 2 hours 45 minutes, and 8 from the one taken at 3 hours 15 minutes. All were found to be identical to the strain administered. The rest of the blood and urine cultures remained negative up to 14 days. Clinical and radiological investigations after the test showed no pathological results. 8 weeks after the experiment the volunteer was still well and had no ill-effects from his experience.

# We repeat this experiment daily in ICUs



# Invasive candidiasis: An overview

- **Most common** invasive fungal infection in hospitalized patients
- Annual incidence: 2-14 per 100,000 persons
- Attributable mortality: 15-25%
- Hospital costs: $40,000-$70,000 per episode

# Changing epidemiology of *Candida* species

| Species | % of Cases | Trend |
|---|---|---|
| *C. albicans* | 40-60% | ↓ |
| *C. glabrata* | 15-25% | ↑ |
| *C. parapsilosis* | 10-20% | → |
| *C. tropicalis* | 5-10% | → |
| *C. krusei* | 2-5% | → |
| *C. auris* | Variable | ↑↑ |

**Note**

Azole exposure drives shift toward non-*albicans* species- but epidemiology varies by geographical local and patient population

The epidemiology continues to evolve. Increased azole use, particularly fluconazole prophylaxis, has selected for *C. glabrata* and *C. krusei*. Infections from *C. parapsilosis* may be spread via healthcare worker's hands are associated with central lines and TPN- in some centers fluconazole-resistant strains are increasing. The emergence of *C. auris* represents a new challenge due to its multidrug resistance and outbreak potential.

# Risk factors for invasive candidiasis

**Host Factors**

- Neutropenia
- Diabetes mellitus
- Recent surgery (abdominal)
- Burns
- Prematurity

**Healthcare Exposures**

- Central venous catheters
- Total parenteral nutrition
- Broad-spectrum antibiotics
- ICU stay >3 days
- Hemodialysis

When you see these risk factors cluster, your suspicion for candidemia should increase. Risk scores such as the “Candida Score” and other prediction tools incorporate these factors. However, no tool replaces clinical judgment. Many patients with multiple risk factors will never develop candidemia. while some with fewer risk factors will.

# Continuum of invasive candidiasis




(Pappas et al., 2018)

# Pathogenesis of Invasive Candidiasis




Figure 1 | **Pathogenesis of invasive candidiasis.** *Candida* spp. can be detected on the mucosal surfaces of ~50–70% of healthy humans. **a** | When breaches in the intestinal barriers occur, for example, after gastrointestinal surgery, *Candida* spp. can disseminate to the abdominal cavity directly and invade the bloodstream (candidaemia). **b** | Under normal conditions, the fungus behaves as a commensal organism without causing disease. **c** | Impairment of immune response, among other factors, can promote fungal overgrowth in the gut and candidaemia, which can lead to deep-seated opportunistic infections in various organs (invasive candidiasis).

- *Candida* are commensals of GI tract, skin, mucosa- Invasion requires breakdown of defenses
- **Biofilm formation** on devices complicates treatment

Understanding parthogenesis helps us target prevention. Candida needs a portal of entry: damaged gut mucosa from chemotherapy, breached skin from catheters, or compromised immunity. The biofilm-forming ability of Candida, especially C. parapsilosis, is why catheter removal is so important.(Pappas et al., 2018)

# Clinical presentations

## Candidemia

- Fever unresponsive to antibiotics
- Often NO localizing signs
- May develop metastatic complications

## Deep-seated

- Hepatosplenic (chronic disseminated)
- Peritonitis
- Endocarditis
- Osteomyelitis

## Endophthalmitis

- Vision changes
- Eye pain
- Occurs in 10-15% of candidemia
- **All patients need dilated eye exam**

Candidemia is often clinically indistinguishable from bacteremia. The lack of localizing signs early on makes diagnosis challenging. Hepatosplenic candidiasis typically presents after neutrophil recovery with persistent fever and elevated alkaline phosphatase. Endophthalmitis is why we mandate dilated eye exams for all candidemia patients.

# Mucosal candidiasis



Esophageal



Cutaneous



Thrush




Vulvo-Vaginal candidiasis

# Disseminated candidiasis



Not disseminated



Disseminated (neutropenic patient)

# Candida endophthalmitis

- Chorioretinitis, endophthalmitis- sight threatening if not recognized early
- Echinocandins do not penetrate vitreous humor- may require intravitreal therapy
- Suggests disseminated disease or prolonged fungemia- check for
  - Endocarditis (uncommon but also consider in patients with prosthetic valves, injection drug users, patients with persistently positive cultures)

Perform within 1 week of diagnosis, or in Neutropenic patients, within 1 week of PMN recovery



FIG. 27.10 *Candida* endophthalmitis. All candidemic patients should be examined for such well-demarcated, white chorioretinal lesions.

# Hepatosplenic candidiasis



Increasing alkaline phosphatase, fever as neutrophils recover

# What cultures miss in invasive candidiasis

**Blood cultures miss**
**50% of cases**




- Sensitivity of blood cultures: 21-71%
- Time to positivity: 2-5 days
- Some patients may die before cultures turn positive
- Tissue infections may be blood culture-negative

# Histopathology



|



| | PAS stain | GMS stain |

# Non-culture diagnostics

| Test | Sensitivity | Specificity | Turnaround |
|---|---|---|---|
| β-D-glucan | 75-80% | 80% | Same day |
| T2Candida | 91% | 99% | 3-5 hours |
| Candida PCR | 85-95% | 90-95% | Variable- Test not well standardized or widely used |

**Tip**

- Combining blood cultures + BDG increases sensitivity to >90%
- Problems with β-D-glucan- Many sources of false positives-i.e. bandages, dialysis filter membranes, antibiotics...etc.
- Many centers only use β-D-glucan to "rule out" invasive candidiasis (higher NPV)

Beta-D-glucan is a pan-fungal marker - it doesn't tell you which fungus. False positives occur with hemodialysis, certain gauzes, and some antibiotics. T2Candida is a magnetic resonance-based assay that detects 5 common *Candida* species directly from blood in 3-5 hours. PCR panels are becoming more available and standardized.

# Treatment algorithm for candidemia




**Note**

Meta-analysis and several clinical trials suggest a survival benefit of starting with echinocandins versus triazoles, but the clinical importance of "fungicidal" vs. "fungistatic" activity for invasive candidiasis is debated.

# Source control is critical

**Central venous catheter removal**

- Associated with improved outcomes
- Reduces mortality by 40-50%
- Should be performed whenever feasible
- Controversial only if:
  - No alternative access
  - CVC tunneled/implanted
  - CVC not clearly the source

**Delay in catheter removal =** increased mortality

Source control is often more important than the antifungal choice. Studies consistently show that delayed or no catheter removal increases mortality. Of course, there are situations where removal is challenging - but we should strongly advocate for it in most cases. If you can't remove the catheter, document why.

# Duration of therapy

- **Uncomplicated candidemia**:
  - 14 days after first negative blood culture
  - **AND** resolution of signs/symptoms
- **Metastatic complications**:
  - Extended duration based on site
  - Endocarditis: 6+ weeks after valve surgery
  - Osteomyelitis: 6-12 months

The 14-day clock starts with the first negative blood culture, not the first positive. This is a common error. Patients with metastatic complications need prolonged therapy. For endophthalmitis, treatment duration depends on severity - consult ophthalmology.

# Antifungal susceptibility testing

| Species | Fluconazole | Echinocandins | Clinical Note |
|---|---|---|---|
| *C. albicans* | S ≤2 | S ≤0.25 | Usually susceptible |
| *C. glabrata* | SDD ≤32 | S ≤0.12 | Check both! |
| *C. krusei* | **Intrinsic R** | S | Never use fluconazole |
| *C. parapsilosis* | S ≤2 | Higher MICs | Fluconazole often preferred, but resistance increasing in some centers |
| *C. auris* | Often R | Variable | Test everything |

Species identification usually drives empiric therapy



SDD-Susceptible dose dependent- fluconazole doses of 12 mg/kg (e.g., 800-1200 mg/day) may be required for treatment

# *Candida auris*: Emerging threat

- First identified in Japan, 2009
- Multidrug resistance common
- Persists in environment
- Causes healthcare outbreaks
- Difficult to identify (often misidentified as other species)
- Associated with high mortality

**Important**

If *C. auris* suspected → Contact infection control immediately

*C. auris* is a game-changer in medical mycology. Unlike other *Candida*, it persists in the environment, enabling horizontal transmission. It's resistant to multiple antifungal classes. MALDI-TOF or molecular methods are needed for accurate identification. Infection control measures are critical.

# Part 3: Cryptococcosis

# Cryptococcosis: Global Impact

- ~220,000 cases annually
- ~180,000 deaths per year
- Leading cause of meningitis in adults with HIV in Africa
- 15% of AIDS-related deaths




*Sub-Saharan Africa bears the greatest burden*

# Epidemiology

- Usually associated with immunocompromised conditions
- > 90% of cases associated with advanced HIV (CD4 <100 cells/μL, transplantation, long-term corticosteroids, cirrhosis)
- In western countries, HIV-associated cases compromise a minority of cases; HIV the dominant cause in resource-poor settings
  - Sub-Saharan Africa
  - South and Southeast Asia
  - Mortality rates can exceed 50% in low-resource settings
  - Co-infections are common in resource-limited settings (25% tuberculosis)
  - Incidence has dropped with widespread availability of ART in Western countries

# *Cryptococcus* species

| Species | Primary Host | Geography | Environment |
|---|---|---|---|
| *C. neoformans* | Immunocompromised | Worldwide | Soil, bird droppings |
| *C. gattii* | Immunocompetent + compromised | Pacific NW, Australia, Tropics | Eucalyptus trees |

> **Note**
>
> *C. gattii* can cause disease in immunocompetent hosts! Some differences in clinical presentation — e.g., greater propensity to cause mass-lesions in brain.

# Pathogenesis




Pathophysiology of cryptococcosis. Cryptococcal spores from the environment (A) initially infect the lungs, where the yeast interacts with alveolar macrophages and produces a Th1 response (B). In hosts with intact immunity, the immune system either eliminates the yeast from the body or creates a granuloma around the fungus and lays dormant. Cryptococcal disease usually does not occur after acute inhalation, rather as a reactivation when the steady state of the immune system is disrupted. In those states of impaired immune control, the yeast can spread haematogenously to other organs, such as the brain (C). When Cryptococcus, either extracellularly, or intracellularly within a macrophage, reaches the blood-brain barrier (BBB), it can enter the brain parenchyma in one of three ways: via a 'Trojan Horse' mechanism by travelling intracellularly inside macrophages across the BBB and being expelled; extracellularly via paracellular mechanisms; and/or transcellularly via transcytosis (D)

(Tugume et al., 2023)

# Immune response to cryptococcosis




(Elsegeiny et al., 2018)

# Pathogenesis

**Virulence Factors:**

1. **Polysaccharide capsule** - Antiphagocytic, immunomodulatory
2. **Melanin production** - Antioxidant protection
3. **Intracellular survival** - Trojan horse to CNS
4. **Titan cells** - Resist phagocytosis



*India ink preparation showing encapsulated yeast*

# Clinical manifestations

## Meningitis

- Subacute onset (1-2 weeks)
- Headache (most common)
- Fever, altered mental status
- Neck stiffness (less than bacterial)
- Cranial nerve palsies
- **Elevated ICP is major killer -** Always ask about vision - papilledema and visual loss indicate elevated ICP

## Pulmonary

- May be asymptomatic
- Cough, dyspnea, chest pain
- Nodules or infiltrates
- Can be incidental finding

## Disseminated

- Skin lesions (umbilicated papules)
- Bone involvement
- Prostate (sanctuary site)

# Cryptococcal skin lesions





Papulonodular umbilicated lesions on the neck and upper trunk-mimic molluscum contagiosum.

# Elevated intracranial pressure

**Critical Complication**

Opening pressure >25 cm $H_2O$ is associated with poor outcomes

**Mechanism:**

- Capsular polysaccharide clogs arachnoid villi
- Impaired CSF reabsorption
- NOT usually communicating hydrocephalus

**Management:**

- Daily LPs if OP >25 cm $H_2O$
- Remove sufficient CSF to reduce by 50% or to <20 cm $H_2O$
- **Avoid corticosteroids** (worse outcomes-COAT trial)
- Mannitol, acetazolamide NOT effective

# ICP management

- ICP management is arguably more important than antifungal choice in the first few days
- Patients die from herniation, not the organism itself.
- Aggressive daily lumbar punctures are the cornerstone. This is uncomfortable but life-saving.
- Lumbar drains or VP shunts may be needed for refractory cases.
- Corticosteroids worsen outcomes - this was shown in the COAT trial.



# Diagnosis of cryptococcosis

| Test | Sensitivity | Specificity | Notes |
|---|---|---|---|
| CSF CrAg (LFA) | 99% | 99% | Point-of-care, rapid |
| Serum CrAg | 99% | 99% | Precedes symptoms |
| India ink | 75-85% | >95% | Less sensitive |
| Culture | 95% | 100% | Takes 3-7 days |

> **Tip**
>
> **Screen all HIV+ patients with CD4 <100 for serum CrAg**

The lateral flow assay for CrAg is a game-changer, especially in resource-limited settings. It's rapid, cheap, and highly accurate. Serum CrAg becomes positive before symptoms develop - this is why we screen. CrAg titers also correlate with fungal burden and can help guide prognosis. Always do an LP if CrAg is positive to rule out CNS involvement.

# Point of care testing CrAg-A game changer



# CSF findings in cryptococcal meningitis

| Parameter | Typical Finding |
|---|---|
| Opening pressure | Elevated (often >25 cm $H_2O$) |
| WBC | Elevated (lymphocyte predominant) |
| Glucose | Low |
| Protein | Elevated |
| CrAg | Positive |

# Treatment phases

| | Induction (2 weeks) | Consolidation (8 weeks) | Maintenance |
|---|---|---|---|
| **Preferred** | L-AMB 10 mg/kg × 1 dose<br>+ Flucytosine × 14 days<br>+ Fluconazole 1200 mg/day × 14 days | Fluconazole 800 mg/day | Fluconazole 200 mg/day |
| **Alternative** | AmB deoxycholate 1 mg/kg/day × 7 days<br>+ Flucytosine × 7 days | — | — |
| **Duration/stop** | — | — | CD4 >100 for ≥3 months on ART |

# The AMBITION trial

- Induction therapy: L-AMB 10 mg/kg x 1 dose *plus*
  - Flucytosine 100 mg/kg/day × 14 days
  - Fluconazole 1200 mg/day × 14 days
- Results:
  - 10-week mortality: 24.8% vs 28.7%
  - Fewer adverse events
- Simplified treatment




**Figure 2. Cumulative All-Cause Mortality Up to Week 10 and Noninferiority Analyses.**

(Iarvis et al.. 2022)

# Cryptococcal meningoencephalitis: Prognostic factors

**Poor outcomes associated with:**

- High CSF fungal burden
- Altered mental status at presentation
- Elevated opening pressure (> 25 cm $H_2O$)
- Low CSF white cell count
- Underlying malignancy
- Inadequate ICP management
- Delayed ART initiation (but too early ALSO problematic)

The CSF fungal burden is perhaps the strongest predictor. This is why quantitative cultures or CrAg titers have prognostic value. Low CSF WBC indicates poor inflammatory response and worse outcome. ART timing is tricky - IRIS can be fatal, but delay allows continued immunosuppression. Current guidance: start ART 4-6 weeks after initiation of antifungal therapy.

# Part 4: Invasive aspergillosis

# Spectrum of Aspergillus disease



# *Aspergillus* species

| Species | Frequency | Clinical Significance |
|---|---|---|
| *A. fumigatus* | 70-80% | Most common; azole resistance emerging |
| *A. flavus* | 10-15% | Sinusitis; aflatoxin producer |
| *A. niger* | 5-10% | Otomycosis; aspergillomas |
| *A. terreus* | 2-5% | **Amphotericin B resistant** |
| *A. nidulans* | Rare | CGD-associated |

# Mode of acquisition



# Mode of acquisition

**Aspergillus Morphology:**

- Conidia (2-3 μm) ubiquitous in air
- Inhaled daily by everyone
- Conidiophores produce chains of spores

**Host Defenses:**

1. Mucociliary clearance
2. Alveolar macrophages kill conidia
3. Neutrophils kill germinating hyphae

> **Note**
>
> Immunocompetent hosts clear thousands of conidia daily without disease

We all breathe in Aspergillus spores constantly. The difference between health and disease is the immune response. Conidia are small enough to reach the alveoli. Macrophages are the first line of defense. If conidia germinate, neutrophils are critical for killing hyphae. This explains why neutropenic patients are at such high risk.

# Risk factors for invasive aspergillosis

**Classic High-Risk:**

- Prolonged neutropenia (≥3 weeks)
- Allogeneic Hematopoetic stem cell transplantation
- Acute leukemia
- Chronic granulomatous disease

**Emerging Risk Groups:**

- High-dose corticosteroids
- Ibrutinib, BTK inhibitors (used for chronic lymphocytic leukemia)
- Solid organ transplant
- ICU patients (post-influenzae, COVID-10)
- COPD with steroids

The risk factor profile is expanding. Classic groups remain important, but we're seeing more IA in patients on novel immunosuppressants. COVID-19 associated pulmonary aspergillosis (CAPA) emerged as a significant concern during the pandemic. Even patients without traditional risk factors can develop IA in the ICU setting.

# Bronchial-Alveolar Phase

**Pathology:**

- Conidia germinate in airways
- Hyphae invade bronchial walls
- Associated inflammation

**Diagnostics:**

- CT: Centrilobular nodules, tree-in-bud
- Serum GM: Often negative
- BAL GM/culture: May be positive

# Angioinvasive Phase: Progression



| Day | Pathology | CT Finding |
|---|---|---|
| 0-3 | Airway invasion | Bronchial thickening, tree-in-bud |
| 3-7 | Hyphal invasion | Macronodule ± halo |
| 5-7 | Hemorrhage, infarction | Dense consolidation |
| 10-12 | Extensive necrosis | Hypodense sign |
| 15-18 | Neutrophil recovery | Air-crescent sign |

This timeline is important for interpreting CT findings. The halo sign appears early when hemorrhage surrounds an infarcted nodule. As disease progresses, the halo disappears and consolidation becomes dense. The air-crescent sign is actually a sign of recovery - it appears when neutrophils return and cavitation begins. The timing of signs depends on degree of immunosuppression and neutropenia- i.e. non-neutropenic patients may have longer periods of airway invasive disease

# CT findings: Halo sign



**Clinical pearl**

The halo sign (ground-glass surrounding a dense nodule) is relatively specific for angioinvasive mold infection in the first week in neutropenic patients

The halo represents hemorrhage surrounding an infarcted, fungal-invaded nodule. It's most useful in the first 5-7 days - after that, it often disappears. While classic for aspergillosis, it can occur with other angioinvasive infections like mucormycosis. Clinical context is essential.

# Spectrum of infections with dissemination



# Disease patterns depend on immune status

**Nodule with Halo Sign**

- Angioinvasive 45%
- Airway invasive 14%
- Both 9%
- Neither 32%

**Centrilobular Nodules**

- Angioinvasive 13%
- Airway invasive 44%
- Both 13%
- Neither 30%

This data from Stergiopoulou and Bergeron shows that CT patterns correlate with underlying pathology. Patients with nodules and halo signs are more likely to have angioinvasive disease. Those with centrilobular nodules more often have airway-invasive disease. This has implications for prognosis and monitoring (Stergiopoulou et al., 2007).

# Galactomannan testing

| Sample | Cutoff | Sensitivity | Specificity |
|---|---|---|---|
| Serum | ≥0.5 ODI | 70-80% | 85-90% |
| BAL | ≥1.0 ODI | 85-90% | 90-95% |

> ⚠ **Warning**
>
> **False Positives:**
>
> - Piperacillin-tazobactam (older literature)
> - Mucositis
> - Some foods
> - Cross-reactivity (*Fusarium*, *Histoplasma*)
>
> **False negatives:**
>
> - Non-neutropenic patients
> - Airway invasive disease
> - **Antifungal prophylaxis**
> - Pediatric patients

Galactomannan is a polysaccharide from the Aspergillus cell wall. It performs better in neutropenic patients than non-neutropenic patients. Bronchial alveolar lavage (BAL) GM has higher sensitivity than serum. Remember that antifungal therapy can make the test negative even if infection is present. Always interpret in clinical context.

# Asperguillus histopathology



|



| | GMS in tissue staining | Calcoflour in BAL washing |

# Diagnosis summary

**Culture and histopathology:**

- BAL culture: Sensitivity 50-60%
- Tissue biopsy: Septate hyphae, acute-angle (45°) branching
- PAS and GMS stains highlight fungal elements

**Biomarkers:**

- Galactomannan (serum and BAL)
- β-D-glucan (pan-fungal)
- Aspergillus PCR (emerging evidence-not avaiable everywhere)

# Treatment: First-line options

**If NO Prior mold-active prophylaxis**

**Voriconazole**

- Loading: 6 mg/kg IV q12h × 2 doses
- Maintenance: 4 mg/kg IV q12h or 200-300 mg PO q12h
- TDM target: 1-5 µg/mL

**Alternatives:**

- Isavuconazole: 200 mg q8h × 6, then 200 mg daily
- Posaconazole: 300 mg q12h × 2, then 300 mg daily

The 2002 Herbrecht trial (Herbrecht et al., 2002) established voriconazole superiority over amphotericin B. Isavuconazole and posaconazole are alternatives with similar efficacy. Voriconazole requires TDM due to variable metabolism and potential toxicity. All triazoles have significant drug interactions - review the medication list!

# Treatment: Breakthrough aspergillosis

⚠ **If receiving posaconazole prophylaxis**

Switch to a different class initially:

- **Liposomal amphotericin B** (3-5 mg/kg/day)
- Reassess reasons for triazole failure
- Consider triazole resistance testing
- May switch to alternative triazole if isolate susceptible and patient stabilizes

Breakthrough on posaconazole prophylaxis raises concerns for resistance or inadequate drug levels. Start with L-AMB while you investigate. Check the posaconazole level - was it therapeutic? If you identify an isolate, send for susceptibility testing. Azole-resistant A. fumigatus is increasing globally.

# Triazole resistance: Emerging threat




- TR34/L98H, TR46/Y121F/T289A mutations
- Environmental origin (agricultural fungicides)
- Prevalence varies geographically
- Associated with treatment failure
- Consider resistance testing in high-risk areas

**Important**

Azole-resistant *Aspergillus* is a growing concern. The main mechanisms are cyp51A mutations that also confer resistance to agricultural triazole fungicides. This environmental selection pressure is driving resistance. Netherlands and UK have highest rates in Europe. Testing is not routine but should be considered in refractory cases.

# Treatment duration and prognosis

**Duration:**

- Minimum 6-12 weeks
- Continue until resolution of lesions
- Continue until reversal of immunosuppression
- Consider secondary prophylaxis

**Prognosis Depends On:**

- Early diagnosis and treatment
- Neutrophil recovery
- Underlying disease control
- Site of infection
- Triazole resistance

Unlike candidemia where we have a set duration, aspergillosis treatment is individualized. Lesions should be followed with serial imaging. Treatment usually continues through subsequent chemotherapy cycles to prevent relapse. Secondary prophylaxis with a triazole is often recommended if the patient will undergo further immunosuppression.

# Part 5: Fusariosis

# Breakthrough Fusarium infection during neutropenia



Fusarium infections infections may present in a similar fashion as aspergillosis but are unique in that they are **more frequently associated with positive blood cultures** with characteristic banana-shaped conidia and meta-static (necrotic) lesions- Ecthyma gangrenosum (differential diagnosis *Asperaillus* or *Pseudomonas* infections)

# Fusarium meta-static skin, ocular and CNS lesions






# Healthcare-associated outbreaks of Fusarium infection

- A multinational outbreak (185 exposed, 9 cases) of nosocomial fusarium meningitis occurred among immunocompetent patients who had undergone cosmetic surgery with epidural anesthesia in Mexico
- The pathogen involved had a high predilection for the brain stem and vertebrobasilar arterial system and was associated with high mortality from vessel injury




(Strona et al., 2024)

# General summary: Fusarium infections

- Most common scenario: Persistent neutropenia
- Most common species:
  - *F. solani* complex (50%), *F. oxysporum** (14%), *F. verticillioides* (10-11%)
- Macroconidia are classic (banana-shaped)
- PCR, rRNA in situ hybridization available, still investigational
- **Positive blood cultures in 30-50% of cases**
- Can be recovered from urine in disseminated infection
- Drugs of choice: L-AMB +/- voriconazole

The role of antifungal susceptibility testing is controversial- however it is clear that *F. solani* show much higher MICs to a wider range of antifungals. The investigational antifungal Fosmanogepix has shown promising activity in healthcare-associated Fusarium meningitis and may become the preferred therapy. However, outcomes are poor in neutropenic patients without neutrophils recovery.

# Part 6: Mucormycosis

# Mucorales: The Scariest Fungi?




> **Important**
>
> **Why so scary?**
>
> - Rapid progression
> - High mortality (40-80%)
> - Requires disfiguring surgery
> - Limited drug options

Twitter poll of ID specialists:

- Mucor spp./Mucormycosis: **44%**
- *Staph aureus*: 24%
- *Candida auris*: 18%
- SARS-CoV-2: 14%

# Ecology of Mucorales









**Environmental Sources:**

- Soil
- Decaying organic matter
- Bread, fruit
- Hospital construction/renovation

**Morphology:**

- Sporangia contain spores
- Large, ribbon-like hyphae
- Pauciseptate (few septa)
- Right-angle branching

# Nosocomial outbreaks



# Risk Factors for Mucormycosis

**Metabolic:**

- Diabetic ketoacidosis
- Uncontrolled diabetes
- Acidosis
- Iron overload
- Deferoxamine use

**Immunologic:**

- Neutropenia
- Hematologic malignancy
- HSCT
- Solid organ transplant
- High-dose corticosteroids

**Others:** Trauma, burns, combat injuries, COVID-19

# Common Mucorales Species

| Genus | Features |
|---|---|
| *Rhizopus* | Most common (especially *R. arrhizus*) |
| *Mucor* | Less common but significant |
| *Lichtheimia* | Common in immunocompromised |
| *Rhizomucor* | More aggressive |
| *Cunninghamella* | Disseminated disease; worst prognosis |

# Pathogenesis




**Important**

**Deferoxamine** acts as a fungal siderophore - increases risk!

**Deferasirox** does NOT increase risk - use this for iron chelation

# Clinical Manifestations: Rhino-orbital-cerebral

**Progression:**

1. Sinusitis, facial pain
2. Nasal congestion, discharge
3. Periorbital edema
4. Black eschar (necrotic tissue)
5. Visual loss, ophthalmoplegia
6. Cavernous sinus thrombosis
7. CNS extension → death



*Rapid progression with nasal bridge necrosis*

# Cavernous sinus invasion




Orbital apex syndrome: A condition that affects the nerves passing through the superior orbital fissure, potentially leading to vision loss, ophthalmoplegia (paralysis or weakness of the eye muscles), and ptosis (drooping of the upper eyelid).

# MRI: “Black Turbinate Sign”




**Imaging Pearl**

Loss of enhancement of the turbinates on contrast MRI indicates devitalized tissue - highly suggestive of mucormycosis in the right clinical context

# Pulmonary Mucormycosis

**CT Features:**

- Multiple nodular infiltrates
- Large pleural effusions
- **Reverse halo sign** (specific)
- Rapid progression




*Reverse halo: ground-glass center with surrounding consolidation*

# Diagnosis of Mucormycosis

> ⚠ **Critical Point**
>
> β-D-glucan and galactomannan do NOT detect Mucorales!

**Diagnostic Approach:**

- Histopathology: Wide, ribbon-like, pauciseptate hyphae
- Culture: Rapid growth (“lid lifter”)
- PCR/sequencing: Available in specialized centers
- MALDI-TOF: For isolate identification

# Treatment Principles

1. **Surgical debridement** - Essential, often repeated
2. **Reversal of predisposing conditions** - Glucose control, reduce immunosuppression
3. **Antifungal therapy** - Start immediately, don't wait for diagnosis
4. **Source control** - Remove infected devices, dead tissue

# Antifungal therapy

**Initial:**

- Liposomal amphotericin B **5-10 mg/kg/day**
- Higher doses for CNS involvement
- May need prolonged IV therapy

**Step-down:**

- Posaconazole or isavuconazole
- For patients responding or with toxicity
- Can be used for consolidation/maintenance

> **Note**
>
> Echinocandins and voriconazole have NO activity alone against Mucorales!

L-AMB is the backbone of therapy. We use high doses - 5 mg/kg routinely, up to 10 mg/kg for CNS disease. This is much higher than for aspergillosis or candidiasis. Posaconazole and isavuconazole are the only oral options with Mucorales activity. Remember: if you started voriconazole empirically thinking it was aspergillosis, you're not treating mucormycosis at all.

# Surgical management



- Often requires disfiguring resections
- Facial prosthetics may be needed
- Survival with surgery: significantly improved
- Reconstructive surgery after cure

> **Important**
>
> **Don't delay surgery** for imaging or culture results in high-risk patients

The surgical images are dramatic, but they represent survival. Patients who receive aggressive surgical debridement have much better outcomes. The disfigurement is real and challenging, but modern reconstructive techniques and prosthetics can achieve remarkable results. Early surgical involvement is critical.

# Part 6: Antifungal toxicities

# Amphotericin B: Nephrotoxicity mechanism




- Afferent arteriole constriction → ↓ renal blood flow
- Tubuloglomerular feedback → further vasoconstriction
- LDL-bound AMB accumulates in tubules (LDL receptors)
- Direct tubular toxicity
- Electrolyte wasting ($K^+$, $Mg^{2+}$, $Na^+$)

Understanding the mechanism helps predict and manage toxicity. The vasoconstriction is rapid - you'll see creatinine rise within days. The electrolyte wasting can be profound and requires aggressive replacement. Monitor potassium, magnesium, and sodium closely.

# Liposomal AMB reduces nephrotoxicity

| Formulation | ≥2-fold SCr Increase |
|---|---|
| Amphotericin B deoxycholate | 26% |
| Liposomal AMB | 10% |

**Mechanism:**

- Liposomes don't undergo glomerular filtration
- Reduced binding to tubular LDL receptors
- Less direct tubular damage

The lipid formulations were developed specifically to reduce nephrotoxicity. They're more expensive but allow us to give higher doses with less toxicity. This is why L-AMB 10 mg/kg is feasible for mucormycosis but would be impossible with deoxycholate. The choice of formulation matters.

# Triazole toxicities overview

| Toxicity | Agent(s) |
|---|---|
| Hepatotoxicity | All (especially voriconazole) |
| QTc prolongation | All (less with isavuconazole) |
| Visual disturbances | Voriconazole |
| Phototoxicity/skin cancer | Voriconazole (chronic) |
| Peripheral neuropathy | Itraconazole > voriconazole |
| Adrenal suppression | Itraconazole, posaconazole |

Each triazole has its own toxicity profile. Voriconazole has the most unique toxicities: visual disturbances occur in up to 30% of patients but are usually transient and benign. Chronic voriconazole increases risk of squamous cell carcinoma - consider switching for long-term prophylaxis. All triazoles are CYP3A4 inhibitors with significant drug interactions.

# Monitoring recommendations

**Triazole monitoring**

- **Baseline**: LFTs, electrolytes, ECG if risk factors
- **Ongoing**: Weekly LFTs initially, then periodically
- **TDM**:
  - Voriconazole: Target 1-5 µg/mL-all patients need monitoring
  - Posaconazole: >1 µg/mL (efficacy cutoff) >1 µg/mL (prophylaxis)
    - Bioavailable of oral tablet > Oral suspension, also lesss drug interactions
  - Isavuconazole: If concerns about efficacy/toxicity
- **Patient counseling**: Visual symptoms, sun protection

Therapeutic drug monitoring is important for voriconazole because of its highly variable pharmacokinetics. CYP2C19 polymorphisms affect metabolism. Levels <1 µg/mL are associated with treatment failure; levels >5 µg/mL with toxicity. For posaconazole, the concern is mainly about adequate exposure. Drug interactions need to be managed actively.

# Summary

# Key Take-Home Messages

Candidiasis | Cryptococcosis | Aspergillosis | Mucormycosis

- Blood cultures miss 50% - use BDG if available- consider empiric treatment in high-risk patients
- Source control (catheter removal) improves outcomes
- Echinocandins first-line for unstable patients
- Dilated eye exam exam recommended for most patients

# Supplementary Slides

The following slides contain additional reference material and case examples.

# Case 1: Candidemia

**Clinical Scenario:**

55-year-old male, recent abdominal surgery, TPN, central line, develops fever on antibiotics.

**Blood culture positive for *Candida glabrata***

- What is your first-line therapy?
- What source control measure is essential?
- What consultation should you obtain?

# Case 2: Cryptococcal Meningitis

**Clinical Scenario:**

32-year-old male, newly diagnosed HIV (CD4 45), 2-week headache, confusion, fever.

LP: OP 32 cm $H_2O$, CrAg positive, WBC 15 (lymphs)

**Management priorities?**

1. ICP management
2. Antifungal therapy
3. ART timing

# Case 3: Suspected Invasive Aspergillosis

**Clinical Scenario:**

60-year-old female, AML induction, neutropenic day 18, persistent fever, new pulmonary nodules with halo sign.

**Questions:**

- What diagnostics would you send?
- What is your empiric therapy?
- How long will you treat?

# Case 4: Rhino-orbital Mucormycosis

**Clinical Scenario:**

58-year-old male, DKA, facial pain, periorbital swelling, nasal eschar.

**Immediate actions:**

1. ENT/Surgery STAT consultation
2. Start L-AMB 5-10 mg/kg NOW
3. Correct metabolic abnormalities
4. Plan for surgical debridement

# EORTC/MSG Criteria: Proven IFI

**Proven Invasive Fungal Infection:**

- Histopathologic evidence of fungal elements from tissue specimen
- OR positive culture from normally sterile site
- OR blood culture positive for fungus (except Aspergillus)

These standardized definitions are used in clinical trials and help categorize infections as proven, probable, or possible. Proven requires either histology or culture from a sterile site. These criteria help standardize diagnosis across different centers.

# EORTC/MSG: Probable IFI

Requires ALL THREE:

1. Host factor (neutropenia, HSCT, SOT, steroids, etc.)
2. Clinical feature (imaging, clinical syndrome)
3. Mycological evidence (GM, BDG, culture from non-sterile site)

Probable IFI is what we diagnose most often in clinical practice. We rarely get tissue diagnosis in severely ill, thrombocytopenic patients. The combination of host factors, imaging, and biomarkers provides sufficient certainty to treat.

# Antifungal Drug Interactions

**Key CYP450 Interactions:**

| Azole | CYP Inhibition | Major Interactions |
|---|---|---|
| Voriconazole | 3A4, 2C19, 2C9 | Calcineurin inhibitors, sirolimus |
| Posaconazole | 3A4 | Calcineurin inhibitors, sirolimus |
| Isavuconazole | 3A4 | Calcineurin inhibitors |
| Fluconazole | 3A4, 2C9 | Warfarin, calcineurin inhibitors |

Drug interactions are among the most challenging aspects of azole management in transplant recipients. Sirolimus levels can increase dramatically with voriconazole - many centers avoid this combination. Always reduce calcineurin inhibitor doses when starting azoles and monitor levels closely.

# Antifungal Dosing Reference

| Drug | Loading | Maintenance |
|---|---|---|
| Fluconazole | 800 mg | 400 mg daily |
| Voriconazole | 6 mg/kg q12h × 2 | 4 mg/kg q12h |
| Posaconazole DR | 300 mg q12h × 2 | 300 mg daily |
| Isavuconazole | 200 mg q8h × 6 | 200 mg daily |
| Caspofungin | 70 mg | 50 mg daily |
| Micafungin | - | 100 mg daily |
| Anidulafungin | 200 mg | 100 mg daily |
| L-AMB | - | 3-5 mg/kg daily |

This quick reference shows standard dosing. Remember hepatic adjustment for caspofungin and anidulafungin, renal adjustment for fluconazole. Voriconazole IV should be avoided in renal impairment due to cyclodextrin accumulation.

# References

Elsegeiny W, Marr KA, Williamson PR. Immunology of cryptococcal infections: Developing a rational approach to patient therapy. Frontiers in Immunology 2018;9:651. https://doi.org/10.3389/fimmu.2018.00651.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, et al. Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis. The New England Journal of Medicine 2002;347:408–15. https://doi.org/10.1056/NEJMoa020191.
Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. The New England Journal of Medicine 2022;386:1109–20. https://doi.org/10.1056/NEJMoa2111904.
Krause W, Matheis H, Wulf K. FUNGÆMIA AND FUNGURIA AFTER ORAL ADMINISTRATION OF CANDIDA ALBICANS. The Lancet 1969;293:598–9. https://doi.org/10.1016/S0140-6736(69)91534-7.
Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nature Reviews Disease Primers 2018;4:18026. https://doi.org/10.1038/nrdp.2018.26.
Stergiopoulou T, Meletiadis J, Roilides E, Kleiner DE, Schaufele R, Roden M, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. American Journal of Clinical Pathology 2007;127:349–55. https://doi.org/10.1309/UJRV9DLC11RM3G8R.
Strong N, Meeks G, Sheth SA, McCullough L, Villalba JA, Tan C, et al. Neurovascular complications of iatrogenic fusarium solani meningitis. New England Journal of Medicine 2024;390:522–9. https://doi.org/10.1056/NEJMoa2308192.
Tugume L, Ssebambulidde K, Kasibante J, Ellis J, Wake RM, Gakuru J, et al. Cryptococcal meningitis. Nature Reviews Disease Primers 2023;9:62. https://doi.org/10.1038/s41572-023-00472-z.